Video Experimental Relacionado
Updated: Feb 20, 2026
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
746
Cambios asociados con inhibidores de SGLT2 en compuestos orgánicos volátiles urinarios en la nefropatía diabética: un
Risa Hara1, Hiroyasu Yamahara2, Yosuke Hirakawa1
1Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nephrology (Carlton, Vic.)
|February 18, 2026
Resumen
Los inhibidores del cotransportador sodio-glucosa 2 (SGLT2) aumentan los cuerpos cetónicos en la orina en pacientes con nefropatía diabética (ND). Este perfil no invasivo de metabolitos urinarios revela cambios metabólicos, lo que ayuda a comprender los inhibidores de SGLT2.
Área de la Ciencia:
- Metabolómica
- Nefrología
- Endocrinología
Sus antecedentes:
- Los inhibidores de SGLT2, inicialmente para la diabetes tipo 2, muestran efectos protectores renales en la nefropatía diabética (ND).
- Los mecanismos metabólicos detrás de las acciones renoprotectoras de los inhibidores de SGLT2 en la ND no se comprenden completamente.
Objetivo del estudio:
- Investigar los mecanismos metabólicos de los inhibidores de SGLT2 en la ND utilizando el perfil no invasivo de metabolitos urinarios.
- Identificar los compuestos orgánicos volátiles (COV) urinarios asociados con el tratamiento con inhibidores de SGLT2 en pacientes con ND.
Principales métodos:
- Se utilizó cromatografía de gases-espectrometría de masas para analizar los COV urinarios en 61 pacientes con ND.
- Los pacientes se clasificaron en grupos tratados y no tratados con inhibidores de SGLT2.
- Se identificaron y cuantificaron 79 COV urinarios; se analizaron estadísticamente las variables clínicas.
Principales resultados:
- Los pacientes tratados con inhibidores de SGLT2 exhibieron niveles urinarios significativamente más altos de acetona y 2-pentanona.
- Estos COV elevados, derivados de cuerpos cetónicos, sugieren una cetogénesis aumentada.
- Los hallazgos fueron consistentes en todos los pacientes e independientes de otras características clínicas.
Conclusiones:
- La terapia con inhibidores de SGLT2 se asocia con un aumento de los COV relacionados con cetonas en la orina, lo que indica un cambio metabólico hacia un metabolismo energético sistémico alterado.
- El perfil de COV urinarios ofrece un método no invasivo prometedor para comprender los mecanismos de los inhibidores de SGLT2 y monitorear los efectos del tratamiento en la ND.
- Este estudio proporciona nuevas perspectivas mecanicistas sobre la protección renal que ofrecen los inhibidores de SGLT2.
Videos de Conceptos Relacionados
01:24Chronic Kidney Disease II: Clinical Manifestations
730
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
730
01:29Urine Studies I: Urinalysis
1.7K
Urinalysis is a widely used diagnostic test that analyzes urine's physical, chemical, and microscopic characteristics. Healthcare providers use it to detect and monitor various health conditions, including renal disease, urinary tract infections (UTIs), diabetes, and metabolic or systemic disorders.Components of UrinalysisUrinalysis consists of three primary components: physical, chemical, and microscopic examination. Each provides unique insights into the urine sample and, by extension, the...
1.7K
01:28Renal Drug Excretion: Tubular Secretion
959
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
959
01:27Glucose Transporters
27.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.6K
01:02Renal Drug Excretion: Glomerular Filtration
1.4K
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
1.4K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
702
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
702